Genmab A/S updated its Articles of Association to reflect a nominal share capital of DKK 62,377,844 and to extend the board's authority to issue new shares, warrants and convertible debt within specified limits through 2029 and 2030. The changes were filed with the U.S. Securities and Exchange Commission on August 12, 2026 through a Form 6-K that included an English translation dated August 11. The revised capital structure follows Genmab's August 11 announcement that it would issue 24,592 new ordinary shares after employees exercised warrants, raising about DKK 37.9 million. The shares, each with a nominal value of DKK 1, were subscribed in cash at DKK 1,334.50 for 4,702 shares, DKK 1,362.50 for 2,069 shares, and DKK 1,615.00 for 17,821 shares. The capital increase, executed without preemption rights for existing shareholders, corresponds to about 0.04% of share capital. Genmab said the new shares carry standard rights, are freely transferable and are expected to be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The updated articles also state that shareholders have no special rights or transfer restrictions. The broader authorization gives the Danish biotechnology company added flexibility to fund growth, support employee incentive programs and use equity or convertible instruments over a multi-year period.